NeuroScios GmbH is a provider of central nervous system (CNS) drug development. The company’s drug development programs include medicinal chemistry, early screening, target identification and validation, in vitro and in vivo pharmacology, absorption, distribution, metabolism, and excretion (ADME), toxicology and safety pharmacology, regulatory support, and clinical trials. Through strategic patenting, NeuroScios analyses the segments of the biomedical patent landscape for gaps to be exploited in accordance with customers’ strategic objectives, conducts freedom-to-operate searches to identify interfering patents and assists with the drafting of its customers’ patent applications. The company provides medical writing services comprising study protocols and reports (Phase I-IV), investigator brochures and annual updates, informed consents, translation of study documents, data safety monitoring board (DSMB) manuals, benefit-risk assessment reports, pre-clinical study reports, expert reports, and summaries, and periodic safety reports. NeuroScios provides statistical and data management services for clients developing treatments for neurodegenerative diseases such as Alzheimer’s, mild cognitive impairment, Parkinson’s, and stroke and psychiatric diseases such as Schizophrenia and depression. Its Data Management services include – case report form (CRF) design, electronic data capture (EDC) data review, data importing to SAS for derivation and structuring prior to analysis, data coding, and quality control.
You have successfully subscribed and will receive the next available issues
CNS Drug Development